Our in vitro final results advise that EAM-2201 should be examined concerning potential in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 activities and competitive inhibition of UGT1A3 action. The potency in the examined compounds to inhibit adenylate cyclase activity was resolute while in https://ericd050qgv4.theideasblog.com/profile